about
The impact of polymer coatings on magnetite nanoparticles performance as MRI contrast agents: a comparative study.Pharmacokinetic consequences of pegylation.Applications of carrier erythrocytes in delivery of biopharmaceuticals.Novel delivery systems for interferons.Hydrogel nanoparticles in drug delivery.Copolymers: efficient carriers for intelligent nanoparticulate drug targeting and gene therapy.Designing PEGylated therapeutic molecules: advantages in ADMET properties.A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach.Carrier erythrocytes: recent advances, present status, current trends and future horizons.Cubosomes: remarkable drug delivery potential.Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug.Design, preparation, and in vitro characterization of a trimodally-targeted nanomagnetic onco-theranostic system for cancer diagnosis and therapy.Artemia salina as a model organism in toxicity assessment of nanoparticles.Biodegradable m-PEG/PCL Core-Shell Micelles: Preparation and Characterization as a Sustained Release Formulation for Curcumin.Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles.Synthesis and characterization of dextran coated magnetite nanoparticles for diagnostics and therapy.The anticancer agent prodigiosin is not a multidrug resistance protein substrate.Simple and Sensitive High-Performance Liquid Chromatography (HPLC) Method with UV Detection for Mycophenolic Acid Assay in Human Plasma. Application to a Bioequivalence Study.pH-Triggered Magnetic-Chitosan Nanogels (MCNs) For Doxorubicin Delivery: Physically vs. Chemically Cross Linking Approach.Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis.A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study.PLA-PEG-PLA copolymer-based polymersomes as nanocarriers for delivery of hydrophilic and hydrophobic drugs: preparation and evaluation with atorvastatin and lisinopril.A simple HPLC method for quantitation of enalaprilat.Benzathine penicillin G: a model for long-term pharmacokinetic comparison of parenteral long-acting formulations.In vitro characterization of human intact erythrocytes loaded by enalaprilat.Relationship of serum ACE inhibition to oral dose of enalapril in normotensive volunteers.Methotrexate-loaded chitosan nanogels as 'Trojan Horses' for drug delivery to brain: preparation and in vitro/in vivo characterization.Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.The impact of preparation parameters on typical attributes of chitosan-heparin nanohydrogels: particle size, loading efficiency, and drug release.Preparation of biodegradable nanoparticles of tri-block PLA-PEG-PLA copolymer and determination of factors controlling the particle size using artificial neural network.Neuropharmacokinetic evaluation of methotrexate-loaded chitosan nanogels.Preparation and optimization of surface-treated methotrexate-loaded nanogels intended for brain delivery.Role of P-glycoprotein in tissue uptake of indinavir in rat.Simple and sensitive high-performance liquid chromatography method for the quantitation of indinavir in rat plasma and central nervous system.Preparation and in-vitro characterization of tramadol-loaded carrier erythrocytes for long-term intravenous delivery.Doxorubicin-conjugated core-shell magnetite nanoparticles as dual-targeting carriers for anticancer drug delivery.Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: comparison of MSF with SBA-15 as drug carriers.Drug-conjugated PLA-PEG-PLA copolymers: a novel approach for controlled delivery of hydrophilic drugs by micelle formationPreparation and characterization of tri-block poly(lactide)-poly(ethylene glycol)-poly(lactide) nanogels for controlled release of naltrexonePreparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b
P50
Q30994212-F01C6734-CE8D-4BA2-A0A3-9FEEB1512757Q36604526-913B5E85-0572-4D64-B6CF-2740D89F5316Q36725488-577F2D34-4D14-4A6F-A31E-28EE8461C002Q36937971-186ABD01-60C7-4079-AE20-651E563A7E49Q37288965-C0533AC1-E7D9-4DDE-9340-BC35C4E262B2Q37946820-B8084560-A352-45AA-B300-758ADD048924Q38089879-6FE643D9-2059-4911-B05E-D481AF439057Q38149966-13D23526-747D-44F7-A258-A6CDED0DAC1CQ38181182-3D588101-A155-46A4-BBA4-D66804FC382DQ38701134-AB7ADF87-5488-4991-91F1-E727EDB3309CQ38775340-BF3D97F5-F927-4CA3-AC20-26C29903BB41Q38807399-588EFA27-06A5-421A-B24E-FC82EE00703DQ38885339-2023489C-3230-42B8-912E-AE97FF98D144Q39041076-10A10BB8-67EB-4EAB-8656-E75224602B58Q40516900-AA8BB2BA-9F0A-4482-B760-24D5C0068361Q41142959-79D09B06-8AF7-44C8-914F-BEAD66CE2D93Q41539054-1E4C0772-E4A3-424F-969B-B0CE72370C06Q42052503-CC6EE0A3-993A-49AC-B146-AC632E45FD70Q42087700-8ED5DE3B-69B2-45C5-BFE9-BB9F7F373E68Q43282509-199D3046-9186-4AAF-A208-8E0692AA4D94Q43282816-B866DD06-1A5D-497C-905C-315A4979B8D0Q43501935-2198021F-6505-4AAF-9557-782647BFCE85Q43555761-FB8D784D-AF4A-4B8E-A613-7B4A6A09059EQ43637031-0433E18B-8259-4550-ABCA-0CC6C528BCBCQ43834446-714EF9AC-B512-42DC-BBC5-D3111CFD961CQ43970879-3269691F-C214-4291-833D-4E7F0E549A70Q44419964-D9F877C6-D181-435D-9720-9C6DA93F0E5BQ46005571-5ADD7EC3-0D91-4137-9D8C-0D3783AB1E32Q46089753-862E4439-DDE4-4233-A3A5-66AA1A2B333DQ47367533-8B1A3E30-8E3D-471D-A609-71478D5F3EB5Q48184908-05825FC4-B905-4B18-A0AE-06FC7B4A246FQ48394110-EDEB7E26-0301-4469-9026-6B889B9A13E5Q48490291-D58CE992-6EE3-4844-BA01-5DA331963B07Q48588261-298ABADD-FF82-447B-AAE7-311AA2BD96FFQ51548972-E19D947E-F2D4-476D-BE4E-2165CDCE277AQ53060380-891DF611-ACFF-44FD-95EA-A607D6C167C4Q53259496-BD961639-617E-4992-A9E4-0605811390BEQ57182105-9ADB06F6-AA43-43E0-8B93-54BA20147703Q57184931-BB38800F-CBFC-440E-A98A-083852B1EE12Q80356571-45137FB3-C877-4A2D-94F2-A692FADA0C16
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mehrdad Hamidi
@ast
Mehrdad Hamidi
@en
Mehrdad Hamidi
@es
Mehrdad Hamidi
@nl
Mehrdad Hamidi
@sl
type
label
Mehrdad Hamidi
@ast
Mehrdad Hamidi
@en
Mehrdad Hamidi
@es
Mehrdad Hamidi
@nl
Mehrdad Hamidi
@sl
prefLabel
Mehrdad Hamidi
@ast
Mehrdad Hamidi
@en
Mehrdad Hamidi
@es
Mehrdad Hamidi
@nl
Mehrdad Hamidi
@sl
P106
P1153
12793079400
P21
P31
P496
0000-0001-7977-5252
P569
2000-01-01T00:00:00Z